"From late 2020 to the summer of 2024, Eli Lilly & Co. ( NYSE: LLY) stock was on a tear, up more than 635%. Last year was a transformative year for the Indianapolis-based pharmaceutical giant, with substantial financial growth driven by its innovative medicines, significant regulatory successes, and continued investment in its pipeline and manufacturing capabilities. On the other hand, it did experience a revenue shortfall in the fourth quarter."
"Now, the share price is 14.0% lower than six months ago, despite an 19.5% pop in the past month after positive Phase 3 results for its experimental oral weight-loss drug and the launch of its Brain Health Matters campaign. The question for investors is whether the latest move is more of the year's ongoing volatility or the stock has begun a sustained run higher."
Eli Lilly's share price increased more than 635% from late 2020 through summer 2024, driven by innovative medicines, regulatory approvals, and investments in pipeline and manufacturing. The company posted substantial revenue and net income growth, yet reported a fourth-quarter revenue shortfall. The stock sits 14.0% below its six-month peak but rose 19.5% in the past month following positive Phase 3 results for an experimental oral weight-loss drug and a Brain Health Matters campaign launch. Investors must weigh whether recent moves reflect ongoing volatility or the start of a sustained multi-year advance. Revenue has grown about 60% since 2016.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]